Gabapentin Tablet
Product Images NDC 71335-2037

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2037). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Equation (Gabapentin Equation)

A formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, with an adjustment factor for female patients. This pharmacokinetic parameter aids dosing considerations for drugs like Gabapentin.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

Line graph showing mean pain scores over 8 weeks comparing placebo and gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis represents mean pain score from 0 to 10. The chart includes a 4-week dose titration period followed by a 4-week fixed dose period, illustrating that gabapentin reduces mean pain scores more than placebo.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph displaying mean pain scores over seven weeks for three groups: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks with baseline and weeks 1 to 7, while the y-axis shows mean pain scores from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) treatments. Study 1 shows 12% responders for placebo and 29% for gabapentin 3600 mg. Study 2 shows 14% for placebo, 32% for gabapentin 1800 mg, and 34% for gabapentin 2400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot showing percentage difference versus daily dose (mg) for Gabapentin across three studies labeled a, b, and c. The X-axis represents daily dose from 600 to 1800 mg, and the Y-axis shows difference percentage ranging from 2% to 22%. Data points are differentiated by study and marked with symbols corresponding to studies a, b, and c.*

FDA Label Image

Gabapentin-structure (Gabapentin Structure)

Chemical structure of gabapentin, showing a cyclohexane ring attached to amino and carboxyl functional groups. The diagram presents the molecular arrangement of the gabapentin active ingredient.*

FDA Label Image

Label (Lbl713352037)

Gabapentin 800 mg tablet label from Bryant Ranch Prepack, showing package quantity of 30 tablets. The label includes storage instructions to keep at room temperature between 20°-25°C (68°-77°F), a warning about possible dizziness, and a reminder to keep all drugs out of reach of children. The label also references the comparison product Neurontin 800 mg tablet by Alkem Laboratories Limited and displays the NDC number 71335-2037-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.